The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its future within the broader market now raises questions about future gains. Copycat versions are eroding patent protection , prompting concerns that investing in companies heavily reliant to Viagra's once-dominant influence could be a speculative